You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTranilast
Accession NumberDB07615
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionTranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
Structure
Thumb
Synonyms
2-{[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino}benzoic acid
External Identifiers
  • MK 341
  • MK-341
  • MK341
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
RizabenNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIHVF50SMY6E
CAS number53902-12-8
WeightAverage: 327.3313
Monoisotopic: 327.110672659
Chemical FormulaC18H17NO5
InChI KeyInChIKey=NZHGWWWHIYHZNX-CSKARUKUSA-N
InChI
InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
IUPAC Name
2-[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enamido]benzoic acid
SMILES
COC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cinnamic acid amides. These are amides of cinnamic acids. Cinnamic acid is an aromatic compound containing a benzene and a carboxylic acid group forming 3-phenylprop-2-enoic acid.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassCinnamic acids and derivatives
Sub ClassCinnamic acid amides
Direct ParentCinnamic acid amides
Alternative Parents
Substituents
  • Cinnamic acid amide
  • O-dimethoxybenzene
  • Dimethoxybenzene
  • N-arylamide
  • Aminobenzoic acid or derivatives
  • Aminobenzoic acid
  • Phenylpropene
  • Benzoic acid
  • Benzoic acid or derivatives
  • Methoxybenzene
  • Styrene
  • Phenol ether
  • Benzoyl
  • Anisole
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Vinylogous amide
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5905
Blood Brain Barrier-0.58
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.6922
P-glycoprotein inhibitor INon-inhibitor0.7716
P-glycoprotein inhibitor IINon-inhibitor0.5842
Renal organic cation transporterNon-inhibitor0.9433
CYP450 2C9 substrateNon-substrate0.6853
CYP450 2D6 substrateNon-substrate0.8054
CYP450 3A4 substrateSubstrate0.5548
CYP450 1A2 substrateNon-inhibitor0.9137
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9451
CYP450 2C19 inhibitorNon-inhibitor0.9167
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7384
Ames testNon AMES toxic0.6665
CarcinogenicityNon-carcinogens0.871
BiodegradationNot ready biodegradable0.8218
Rat acute toxicity2.4428 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9921
hERG inhibition (predictor II)Non-inhibitor0.8008
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0084 mg/mLALOGPS
logP2.89ALOGPS
logP3.56ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.55ChemAxon
pKa (Strongest Basic)-2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area84.86 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity91.52 m3·mol-1ChemAxon
Polarizability34.2 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Tranilast.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Tranilast.
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Tranilast.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Tranilast.
AbciximabTranilast may increase the anticoagulant activities of Abciximab.
AbciximabAbciximab may increase the antiplatelet activities of Tranilast.
AcebutololTranilast may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tranilast.
AcenocoumarolTranilast may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tranilast.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tranilast.
Alendronic acidThe risk or severity of adverse effects can be increased when Tranilast is combined with Alendronic acid.
AlfuzosinAlfuzosin may increase the hypotensive activities of Tranilast.
AliskirenTranilast may decrease the antihypertensive activities of Aliskiren.
AlprenololTranilast may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tranilast.
AlprostadilAlprostadil may increase the antiplatelet activities of Tranilast.
AlteplaseTranilast may increase the anticoagulant activities of Alteplase.
ALX-0081Tranilast may increase the anticoagulant activities of ALX-0081.
AmikacinTranilast may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideTranilast may decrease the antihypertensive activities of Amiloride.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Tranilast is combined with Aminosalicylic Acid.
AmobarbitalThe metabolism of Tranilast can be increased when combined with Amobarbital.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Tranilast.
AmphetamineAmphetamine may decrease the sedative activities of Tranilast.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tranilast.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Tranilast.
AnagrelideTranilast may increase the anticoagulant activities of Anagrelide.
AnagrelideAnagrelide may increase the antiplatelet activities of Tranilast.
AncrodTranilast may increase the anticoagulant activities of Ancrod.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Tranilast.
AnistreplaseTranilast may increase the anticoagulant activities of Anistreplase.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tranilast.
Antithrombin III humanTranilast may increase the anticoagulant activities of Antithrombin III human.
ApixabanTranilast may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Tranilast.
ArdeparinTranilast may increase the anticoagulant activities of Ardeparin.
ArgatrobanTranilast may increase the anticoagulant activities of Argatroban.
ArgatrobanArgatroban may increase the antiplatelet activities of Tranilast.
ArotinololTranilast may decrease the antihypertensive activities of Arotinolol.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Tranilast.
AstaxanthinTranilast may increase the anticoagulant activities of Astaxanthin.
AtenololTranilast may decrease the antihypertensive activities of Atenolol.
AtosibanThe risk or severity of adverse effects can be increased when Tranilast is combined with Atosiban.
Atracurium besylateTranilast may increase the neuromuscular blocking activities of Atracurium besylate.
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tranilast.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tranilast.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tranilast.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Tranilast.
BalsalazideTranilast may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Tranilast.
BarbitalThe metabolism of Tranilast can be increased when combined with Barbital.
BatroxobinTranilast may increase the anticoagulant activities of Batroxobin.
BecaplerminTranilast may increase the anticoagulant activities of Becaplermin.
BefunololTranilast may decrease the antihypertensive activities of Befunolol.
BemiparinTranilast may increase the anticoagulant activities of Bemiparin.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Tranilast.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tranilast.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tranilast.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Tranilast.
BenzphetamineBenzphetamine may decrease the sedative activities of Tranilast.
Benzylpenicilloyl PolylysineTranilast may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BeraprostTranilast may increase the anticoagulant activities of Beraprost.
BeraprostBeraprost may increase the antiplatelet activities of Tranilast.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Tranilast.
BetaxololTranilast may decrease the antihypertensive activities of Betaxolol.
BevantololTranilast may decrease the antihypertensive activities of Bevantolol.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Tranilast.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tranilast.
BisoprololTranilast may decrease the antihypertensive activities of Bisoprolol.
BivalirudinTranilast may increase the anticoagulant activities of Bivalirudin.
BopindololTranilast may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tranilast.
BufuralolTranilast may decrease the antihypertensive activities of Bufuralol.
BumetanideTranilast may decrease the diuretic activities of Bumetanide.
BupranololTranilast may decrease the antihypertensive activities of Bupranolol.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Tranilast.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Tranilast.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tranilast.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Tranilast.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tranilast.
CangrelorTranilast may increase the anticoagulant activities of Cangrelor.
CangrelorCangrelor may increase the antiplatelet activities of Tranilast.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Tranilast.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tranilast.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Tranilast.
CarteololTranilast may decrease the antihypertensive activities of Carteolol.
CarvedilolTranilast may decrease the antihypertensive activities of Carvedilol.
CarvedilolCarvedilol may increase the hypotensive activities of Tranilast.
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Tranilast.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tranilast.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tranilast.
CeliprololTranilast may decrease the antihypertensive activities of Celiprolol.
CertoparinTranilast may increase the anticoagulant activities of Certoparin.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Tranilast.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tranilast.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tranilast.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Tranilast.
ChlorphentermineChlorphentermine may decrease the sedative activities of Tranilast.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tranilast.
CholestyramineCholestyramine can cause a decrease in the absorption of Tranilast resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Tranilast.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tranilast.
CilostazolTranilast may increase the anticoagulant activities of Cilostazol.
CilostazolCilostazol may increase the antiplatelet activities of Tranilast.
CimetidineThe serum concentration of Tranilast can be increased when it is combined with Cimetidine.
Citric AcidTranilast may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Tranilast is combined with Clonixin.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tranilast.
ClopidogrelClopidogrel may increase the antiplatelet activities of Tranilast.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tranilast.
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Tranilast.
ColesevelamColesevelam can cause a decrease in the absorption of Tranilast resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Tranilast resulting in a reduced serum concentration and potentially a decrease in efficacy.
CollagenaseThe risk or severity of adverse effects can be increased when Tranilast is combined with Collagenase.
CyclosporineTranilast may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tranilast.
D-LimoneneThe risk or severity of adverse effects can be increased when Tranilast is combined with D-Limonene.
Dabigatran etexilateTranilast may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinTranilast may increase the anticoagulant activities of Dalteparin.
DanaparoidTranilast may increase the anticoagulant activities of Danaparoid.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Tranilast.
DasatinibDasatinib may increase the anticoagulant activities of Tranilast.
DaunorubicinTranilast may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Tranilast.
DeferasiroxThe risk or severity of adverse effects can be increased when Tranilast is combined with Deferasirox.
DefibrotideTranilast may increase the anticoagulant activities of Defibrotide.
DefibrotideDefibrotide may increase the antiplatelet activities of Tranilast.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Tranilast is combined with Deoxycholic Acid.
DesirudinTranilast may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Tranilast is combined with Desmopressin.
DesmoteplaseTranilast may increase the anticoagulant activities of Desmoteplase.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tranilast.
DextranTranilast may increase the anticoagulant activities of Dextran.
Dextran 40Tranilast may increase the anticoagulant activities of Dextran 40.
Dextran 70Tranilast may increase the anticoagulant activities of Dextran 70.
Dextran 75Tranilast may increase the anticoagulant activities of Dextran 75.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Tranilast.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tranilast.
DicoumarolTranilast may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tranilast.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tranilast.
DihydrostreptomycinTranilast may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tranilast.
DipyridamoleTranilast may increase the anticoagulant activities of Dipyridamole.
DipyridamoleDipyridamole may increase the antiplatelet activities of Tranilast.
DitazoleTranilast may increase the anticoagulant activities of Ditazole.
DoxazosinDoxazosin may increase the hypotensive activities of Tranilast.
DoxorubicinTranilast may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneTranilast may increase the hyperkalemic activities of Drospirenone.
Drotrecogin alfaTranilast may increase the anticoagulant activities of Drotrecogin alfa.
DroxicamThe risk or severity of adverse effects can be increased when Tranilast is combined with Droxicam.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Tranilast.
Edetic AcidTranilast may increase the anticoagulant activities of Edetic Acid.
EdoxabanTranilast may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Tranilast can be decreased when it is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Tranilast.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Tranilast.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tranilast.
EnoxaparinTranilast may increase the anticoagulant activities of Enoxaparin.
EpinastineEpinastine may increase the antiplatelet activities of Tranilast.
EpirizoleThe risk or severity of adverse effects can be increased when Tranilast is combined with Epirizole.
EpirubicinTranilast may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneTranilast may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tranilast.
EpoprostenolEpoprostenol may increase the antiplatelet activities of Tranilast.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tranilast.
EptifibatideTranilast may increase the anticoagulant activities of Eptifibatide.
EptifibatideEptifibatide may increase the antiplatelet activities of Tranilast.
EsmololTranilast may decrease the antihypertensive activities of Esmolol.
Etacrynic acidTranilast may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tranilast.
Ethyl biscoumacetateTranilast may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Tranilast is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Tranilast.
EtofenamateThe risk or severity of adverse effects can be increased when Tranilast is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tranilast.
Evening primrose oilThe risk or severity of adverse effects can be increased when Tranilast is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Tranilast.
FenbufenThe risk or severity of adverse effects can be increased when Tranilast is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tranilast.
FibrinolysinTranilast may increase the anticoagulant activities of Fibrinolysin.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tranilast.
FluconazoleThe serum concentration of Tranilast can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Tranilast.
FlunixinThe risk or severity of adverse effects can be increased when Tranilast is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tranilast.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tranilast.
Fondaparinux sodiumTranilast may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tranilast.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tranilast.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Tranilast.
FramycetinTranilast may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideTranilast may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tranilast.
GentamicinTranilast may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
GlucosamineGlucosamine may increase the antiplatelet activities of Tranilast.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Tranilast.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Tranilast.
HaloperidolThe risk or severity of adverse effects can be increased when Tranilast is combined with Haloperidol.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Tranilast.
HeparinTranilast may increase the anticoagulant activities of Heparin.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Tranilast.
HexobarbitalThe metabolism of Tranilast can be increased when combined with Hexobarbital.
HirulogTranilast may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Tranilast.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tranilast.
HydralazineTranilast may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tranilast.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tranilast.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Tranilast.
Hygromycin BTranilast may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Ibandronate.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Tranilast is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Tranilast.
IbudilastIbudilast may increase the antiplatelet activities of Tranilast.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tranilast.
IbuproxamThe risk or severity of adverse effects can be increased when Tranilast is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Tranilast.
Icosapent ethylTranilast may increase the antiplatelet activities of Icosapent ethyl.
IdarubicinTranilast may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IfenprodilTranilast may increase the antiplatelet activities of Ifenprodil.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tranilast.
IloprostIloprost may increase the antiplatelet activities of Tranilast.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tranilast.
IndenololTranilast may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tranilast.
IndoprofenThe risk or severity of adverse effects can be increased when Tranilast is combined with Indoprofen.
IndoraminIndoramin may increase the hypotensive activities of Tranilast.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tranilast.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Tranilast.
IsoxicamThe risk or severity of adverse effects can be increased when Tranilast is combined with Isoxicam.
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Tranilast.
KanamycinTranilast may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Kebuzone.
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Tranilast.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tranilast.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tranilast.
LabetalolTranilast may decrease the antihypertensive activities of Labetalol.
LabetalolLabetalol may increase the hypotensive activities of Tranilast.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Tranilast.
LepirudinTranilast may increase the anticoagulant activities of Lepirudin.
LevobunololTranilast may decrease the antihypertensive activities of Levobunolol.
LimaprostLimaprost may increase the antiplatelet activities of Tranilast.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Tranilast.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tranilast.
LithiumThe serum concentration of Lithium can be increased when it is combined with Tranilast.
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tranilast.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tranilast.
LoxoprofenThe risk or severity of adverse effects can be increased when Tranilast is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tranilast.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Tranilast.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Tranilast is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Tranilast is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tranilast.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Tranilast is combined with Magnesium Sulfate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tranilast.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tranilast.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tranilast.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tranilast.
MephentermineMephentermine may decrease the sedative activities of Tranilast.
MesalazineTranilast may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Tranilast.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Tranilast.
MethamphetamineMethamphetamine may decrease the sedative activities of Tranilast.
MethohexitalThe metabolism of Tranilast can be increased when combined with Methohexital.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tranilast.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tranilast.
MethylphenobarbitalThe metabolism of Tranilast can be increased when combined with Methylphenobarbital.
MetipranololTranilast may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tranilast.
MetoprololTranilast may decrease the antihypertensive activities of Metoprolol.
MetrizamideTranilast may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Tranilast.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Tranilast.
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Tranilast.
MilrinoneMilrinone may increase the antiplatelet activities of Tranilast.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Tranilast.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tranilast.
MivacuriumTranilast may increase the neuromuscular blocking activities of Mivacurium.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Tranilast.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Tranilast.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tranilast.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tranilast.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tranilast.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Tranilast.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tranilast.
NadololTranilast may decrease the antihypertensive activities of Nadolol.
NadroparinTranilast may increase the anticoagulant activities of Nadroparin.
NafcillinThe metabolism of Tranilast can be increased when combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Tranilast.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Tranilast.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Tranilast.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Tranilast.
NeomycinTranilast may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tranilast.
NetilmicinTranilast may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tranilast.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tranilast.
NitroprussideTranilast may increase the hypotensive activities of Nitroprusside.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Tranilast.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Tranilast.
ObinutuzumabThe risk or severity of adverse effects can be increased when Tranilast is combined with Obinutuzumab.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tranilast.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tranilast.
OlsalazineTranilast may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tranilast.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Tranilast is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Tranilast.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Tranilast.
OrgoteinThe risk or severity of adverse effects can be increased when Tranilast is combined with Orgotein.
OtamixabanTranilast may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tranilast.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Tranilast.
OxprenololTranilast may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tranilast.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Tranilast.
PamidronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Tranilast is combined with Parecoxib.
ParnaparinTranilast may increase the anticoagulant activities of Parnaparin.
ParomomycinTranilast may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololTranilast may decrease the antihypertensive activities of Penbutolol.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Tranilast.
PentobarbitalThe metabolism of Tranilast can be increased when combined with Pentobarbital.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tranilast.
Pentosan PolysulfateTranilast may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Tranilast.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Tranilast.
PhenindioneTranilast may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Tranilast can be increased when combined with Phenobarbital.
PhenprocoumonTranilast may increase the anticoagulant activities of Phenprocoumon.
PhenterminePhentermine may decrease the sedative activities of Tranilast.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tranilast.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Tranilast.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tranilast.
PindololTranilast may decrease the antihypertensive activities of Pindolol.
PiretanideTranilast may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tranilast.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tranilast.
PlasminTranilast may increase the anticoagulant activities of Plasmin.
PlicamycinTranilast may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tranilast.
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Tranilast.
PractololTranilast may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tranilast.
PrasugrelTranilast may increase the anticoagulant activities of Prasugrel.
PrasugrelPrasugrel may increase the antiplatelet activities of Tranilast.
PrazosinPrazosin may increase the hypotensive activities of Tranilast.
PrimidoneThe metabolism of Tranilast can be increased when combined with Primidone.
ProbenecidThe serum concentration of Tranilast can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Tranilast is combined with Propacetamol.
PropranololTranilast may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Tranilast.
Protein CTranilast may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeTranilast may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Tranilast.
PuromycinTranilast may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Tranilast.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tranilast.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Tranilast.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Tranilast.
RapacuroniumTranilast may increase the neuromuscular blocking activities of Rapacuronium.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tranilast.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tranilast.
ReteplaseTranilast may increase the anticoagulant activities of Reteplase.
ReviparinTranilast may increase the anticoagulant activities of Reviparin.
RibostamycinTranilast may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RidogrelRidogrel may increase the antiplatelet activities of Tranilast.
RisedronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Risedronate.
RivaroxabanTranilast may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Tranilast.
RosiglitazoneTranilast may increase the anticoagulant activities of Rosiglitazone.
SalicylamideThe risk or severity of adverse effects can be increased when Tranilast is combined with Salicylamide.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Tranilast.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tranilast.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Tranilast.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tranilast.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tranilast.
SCH-530348SCH-530348 may increase the antiplatelet activities of Tranilast.
SecobarbitalThe metabolism of Tranilast can be increased when combined with Secobarbital.
SelexipagTranilast may increase the anticoagulant activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tranilast.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Tranilast.
SevofluraneSevoflurane may increase the antiplatelet activities of Tranilast.
SilodosinSilodosin may increase the hypotensive activities of Tranilast.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Tranilast.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Tranilast.
SotalolTranilast may decrease the antihypertensive activities of Sotalol.
SpectinomycinTranilast may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Tranilast.
SpironolactoneTranilast may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Tranilast.
StreptokinaseTranilast may increase the anticoagulant activities of Streptokinase.
StreptomycinTranilast may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinTranilast may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Tranilast.
SulfasalazineTranilast may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tranilast.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Tranilast.
SulodexideTranilast may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Tranilast.
TacrolimusTranilast may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tranilast.
TamsulosinTamsulosin may increase the hypotensive activities of Tranilast.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tranilast.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Tranilast.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tranilast.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Tranilast.
TenecteplaseTranilast may increase the anticoagulant activities of Tenecteplase.
TenofovirThe risk or severity of adverse effects can be increased when Tranilast is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tranilast.
TepoxalinThe risk or severity of adverse effects can be increased when Tranilast is combined with Tepoxalin.
TerazosinTerazosin may increase the hypotensive activities of Tranilast.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Tranilast.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Tranilast.
TeriflunomideThe risk or severity of adverse effects can be increased when Tranilast is combined with Teriflunomide.
TesmilifeneTesmilifene may increase the antiplatelet activities of Tranilast.
ThiamylalThe metabolism of Tranilast can be increased when combined with Thiamylal.
ThiopentalThe metabolism of Tranilast can be increased when combined with Thiopental.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Tranilast.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tranilast.
TicagrelorTranilast may increase the anticoagulant activities of Ticagrelor.
TiclopidineTranilast may increase the anticoagulant activities of Ticlopidine.
TiclopidineTiclopidine may increase the antiplatelet activities of Tranilast.
TiludronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Tiludronate.
TimololTranilast may decrease the antihypertensive activities of Timolol.
TinzaparinTranilast may increase the anticoagulant activities of Tinzaparin.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Tranilast.
TipranavirTipranavir may increase the antiplatelet activities of Tranilast.
TirofibanTranilast may increase the anticoagulant activities of Tirofiban.
TirofibanTirofiban may increase the antiplatelet activities of Tranilast.
TobramycinTranilast may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tranilast is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tranilast.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Tranilast.
TorasemideTranilast may decrease the diuretic activities of Torasemide.
TositumomabThe risk or severity of adverse effects can be increased when Tranilast is combined with Tositumomab.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tranilast.
TrapidilTranilast may increase the antiplatelet activities of Trapidil.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tranilast.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tranilast.
TreprostinilTranilast may increase the anticoagulant activities of Treprostinil.
TriamtereneTranilast may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tranilast.
TriflusalTranilast may increase the anticoagulant activities of Triflusal.
TriflusalTriflusal may increase the antiplatelet activities of Tranilast.
TrimazosinTrimazosin may increase the hypotensive activities of Tranilast.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Tranilast.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tranilast.
UrokinaseTranilast may increase the anticoagulant activities of Urokinase.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Tranilast.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tranilast.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Tranilast.
Vitamin EVitamin E may increase the antiplatelet activities of Tranilast.
VorapaxarTranilast may increase the anticoagulant activities of Vorapaxar.
VorapaxarVorapaxar may increase the antiplatelet activities of Tranilast.
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Tranilast.
WarfarinThe risk or severity of adverse effects can be increased when Tranilast is combined with Warfarin.
XimelagatranTranilast may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tranilast.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Tranilast.
Zoledronic acidThe risk or severity of adverse effects can be increased when Tranilast is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tranilast.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein homodimerization activity
Specific Function:
Bifunctional enzyme which catalyzes both the conversion of PGH2 to PGD2, a prostaglandin involved in smooth muscle contraction/relaxation and a potent inhibitor of platelet aggregation, and the conjugation of glutathione with a wide range of aryl halides and organic isothiocyanates. Also exhibits low glutathione-peroxidase activity towards cumene hydroperoxide.
Gene Name:
HPGDS
Uniprot ID:
O60760
Molecular Weight:
23343.65 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on September 15, 2010 15:24 / Updated on August 17, 2016 12:24